JANSSEN-CILAG is one of the world’s leading research-based pharmaceutical companies. Operating as part of the Johnson & Johnson family of companies, Janssen-Cilag is committed to discovering and delivering innovative medicines.
In 2008, with the launch of its first antibiotic product in the UK, the company took its first steps towards aiding the fight against growing antimicrobial resistance – one of the biggest challenges facing the NHS. Janssen-Cilag plans to create a diverse portfolio of products that can treat a range of infections to meet unmet medical needs. It is also committed to developing partnerships with clinicians and providing services that address medical education requirements. Through a collaborative approach, the company aims to help optimise and control the use of antimicrobials, maximise clinical outcomes and help to extend the useful life of these vital medicines.
